Advertisement

Current Diabetes Reports

, 18:64 | Cite as

Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach

  • Josephine L. Harrington
  • Natalia de Albuquerque Rocha
  • Kershaw V. Patel
  • Subodh Verma
  • Darren K. McGuire
Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Pharmacologic Treatment of Type 2 Diabetes

Abstract

Purpose of Review

With recent cardiovascular outcome trial (CVOT) results for antihyperglycemic medications, the treatment algorithm for patients with type 2 diabetes (T2DM) and atherosclerotic vascular disease (ASCVD) requires revision.

Recent Findings

All completed CVOTs have demonstrated CV safety of the tested medications, with some trials demonstrating CV efficacy. While metformin remains the first-line recommended medication for T2DM, 18–37% of the patients enrolled in the completed CVOTs were not treated with metformin, providing substantial power to assess CV outcomes independent of metformin. The safety and tolerability of metformin are indisputable, but there are no robust data proving its efficacy for either macro or microvascular disease outcomes. We should reconsider the primacy of metformin in the management of T2DM in patients with ASCVD.

Summary

This article will review the evidence for CV effects of antihyperglycemic agents (AHAs), and propose an evidence-based treatment algorithm for patients with T2DM and ASCVD.

Keywords

Type 2 diabetes Atherosclerotic cardiovascular disease Coronary artery disease HbA1c Metformin Cardiovascular outcomes trials 

Notes

Compliance with Ethical Standards

Conflict of Interest

Josephine L. Harrington, Natalia de Albuquerque Rocha, and Kershaw V. Patel declare that they have no conflict of interest.

Subodh Verma has received support from Amgen, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, and Sanofi.

Darren K. McGuire has received support for clinical trial leadership from AstraZeneca, Sanofi Aventis, Janssen, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, Esperion; and honoraria for consultancy from AstraZeneca, Sanofi Aventis, Lilly US, Boehringer Ingelheim, Merck & Co, Pfizer, Metavant, and Novo Nordisk.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596–615.CrossRefGoogle Scholar
  2. 2.
    National Diabetes Statistics Report. | Data & Statistics | Diabetes | CDC. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html. Accessed 24 Mar 2018.
  3. 3.
    Roglic G, World Health Organization Global report on diabetes. World Health Organization, Geneva, Switzerland. http://www.who.int/diabetes/global-report/en/. Accessed 24 Mar 3018.
  4. 4.
    Patel A, MacMahon S, on behalf of the ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 358:2560–72.Google Scholar
  5. 5.
    Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998;21:1138–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMedGoogle Scholar
  9. 9.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:837–53.Google Scholar
  10. 10.
    Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–18.CrossRefPubMedGoogle Scholar
  11. 11.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Gore MO, McGuire DK. Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur Heart J. 2011;32:1832–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 19:Suppl:789–830.Google Scholar
  15. 15.
    Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Nathan DM. Finding new treatments for diabetes—how many, how fast . . . how good? N Engl J Med. 2007;356:437–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Fleming A. FDA approach to the regulation of drugs for diabetes. Am Heart J. 1999;138:S338–45.CrossRefPubMedGoogle Scholar
  19. 19.
    Gore MO, McGuire DK. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. Curr Cardiol Rep. 2009;11:258–63.CrossRefPubMedGoogle Scholar
  20. 20.
    •• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117–28. CVOT showing CV superiority for empagliflozin, an SGLT2i Google Scholar
  21. 21.
    •• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377:644–57. CVOT showing CV superiority for canagliflozin, an SGLT2i Google Scholar
  22. 22.
    •• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 375:311–22. CVOT showing CV superiority for liraglutide, a GLP-1RA Google Scholar
  23. 23.
    •• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 375:1834–44. CVOT showing CV superiority for semaglutide, a GLP-1RA. Google Scholar
  24. 24.
    Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 358:2545–59.Google Scholar
  25. 25.
    Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.CrossRefPubMedGoogle Scholar
  26. 26.
    • Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 Diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38:140–9. Current Guidelines on T2DM management by the American Diabetes Association and European Association for the Study of Diabetes Google Scholar
  27. 27.
    • AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm 2018. In: Am. Assoc. Clin. Endocrinol. https://www.aace.com/publications/algorithm. Accessed 2 Apr 2018 Current Guidelines on T2DM management by the American Association of Endocrinologists and American College of Endocrinology.
  28. 28.
    • International Diabetes Federation. Global Guideline for Type 2 Diabetes. https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes. Accessed 6 Apr 2018 Current Guidelines on T2DM management by the International Diabetes Federation.
  29. 29.
    American Diabetes Association 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2017;41:S73–85.CrossRefGoogle Scholar
  30. 30.
    • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet Lond Engl. 1998;352:854–65. Study that suggested that there was a decrease in MI and CV mortality rate in patients randomized to metformin. This study played a large role in metformin’s ubiquity CrossRefGoogle Scholar
  31. 31.
    Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    McCall AL. Insulin therapy and hypoglycemia. Endocrinol Metab Clin N Am. 2012;41:57–87.CrossRefGoogle Scholar
  33. 33.
    Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol. 2016;81:496–504.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60:1566–76.CrossRefPubMedGoogle Scholar
  35. 35.
    Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 1972;21:976–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev CD002967.Google Scholar
  37. 37.
    Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–75.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    • Diabetes Canada | Clinical Practice Guidelines - 2018 Full Guidelines. http://guidelines.diabetes.ca/fullguidelines. Accessed 9 May 2018. Current guidelines on T2DM management by Diabetes Canada.
  39. 39.
    Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care. 2007;30:e129.CrossRefPubMedGoogle Scholar
  40. 40.
    Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to moderate renal insufficiency. Diabetes Care. 2011;34(6):1431–7.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed 26 Apr 2018.
  42. 42.
    WHO | WHO Model Lists of Essential Medicines. In: WHO. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 27 Apr 2018.
  43. 43.
    Boussageon R, Gueyffier F, Cornu C. Metformin as firstline treatment for type 2 diabetes: are we sure? BMJ. 2016;352:h6748.CrossRefPubMedGoogle Scholar
  44. 44.
    • Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel J-P, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9:e1001204. A meta-analysis of metformin trials (including UKPDS 34) that was unable to exclude reductions or increases in all-cause mortality or CV mortality associated with metformin use.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740–51.CrossRefPubMedGoogle Scholar
  46. 46.
    Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care. 2001;24:989–94.CrossRefPubMedGoogle Scholar
  47. 47.
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter Metformin Study Group. N Engl J Med. 1995;333:541–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002;51:3479–85.CrossRefPubMedGoogle Scholar
  49. 49.
    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660–5.CrossRefPubMedGoogle Scholar
  50. 50.
    White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.CrossRefPubMedGoogle Scholar
  51. 51.
    Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.CrossRefPubMedGoogle Scholar
  52. 52.
    Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42.CrossRefPubMedGoogle Scholar
  53. 53.
    Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.CrossRefPubMedGoogle Scholar
  54. 54.
    Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723–32.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.CrossRefPubMedGoogle Scholar
  56. 56.
    Standards of Medical Care in Diabetes | American Diabetes Association. https://professional.diabetes.org/content-page/standards-medical-care-diabetes. Accessed 9 May 2018.
  57. 57.
    Bergmark BA, Bhatt DL, McGuire D, et al. Abstract 16764: metformin use and clinical outcomes among patients with diabetes mellitus and heart failure or kidney dysfunction—observations from the SAVOR-TIMI 53 trial. Circulation. 2016;134:A16764.Google Scholar
  58. 58.
    Crowley MJ, Williams JW, Kosinski AS, D’Alessio DA, Buse JB. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Care. 2017;  https://doi.org/10.2337/dc17-1528.
  59. 59.
    U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed 31 Mar 2018.
  60. 60.
    U.S. Food and Drug Administration. Victoza (liraglutide [rDNA origin] injection. Package Insert.Google Scholar
  61. 61.
    Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet Lond Engl. 2005;366:1279–89.CrossRefGoogle Scholar
  62. 62.
    Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet. 2007;369:189–90.CrossRefPubMedGoogle Scholar
  63. 63.
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–8.CrossRefPubMedGoogle Scholar
  64. 64.
    McGuire DK, de Werf FV, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:126–35.CrossRefPubMedGoogle Scholar
  65. 65.
    Scirica BM, Braunwald E, Raz I et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 Randomized Trial. Circulation CIRCULATIONAHA.114.010389.Google Scholar
  66. 66.
    Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–76.CrossRefPubMedGoogle Scholar
  67. 67.
    Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877–86.CrossRefPubMedGoogle Scholar
  68. 68.
    Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.CrossRefPubMedGoogle Scholar
  69. 69.
    Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and renal microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17:39.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res. 2013;10:302–14.CrossRefPubMedGoogle Scholar
  71. 71.
    Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304–11.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601–10.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:938–53.CrossRefPubMedGoogle Scholar
  74. 74.
    Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st cardiovascular outcome trial (CVOT) summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;  https://doi.org/10.1186/s12933-016-0357-x.
  75. 75.
    Patel KV, de Albuquerque Rocha N, McGuire DK. Diabetes medications and cardiovascular outcome trials: lessons learned. Cleve Clin J Med. 2017;84:759–67.CrossRefPubMedGoogle Scholar
  76. 76.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.CrossRefPubMedGoogle Scholar
  78. 78.
    Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–8.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71:471–6.  https://doi.org/10.1016/j.jjcc.2017.12.004.CrossRefPubMedGoogle Scholar
  80. 80.
    Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03036124. Accessed 10 May 2018.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Josephine L. Harrington
    • 1
  • Natalia de Albuquerque Rocha
    • 1
    • 2
  • Kershaw V. Patel
    • 1
    • 2
  • Subodh Verma
    • 4
  • Darren K. McGuire
    • 1
    • 2
    • 3
  1. 1.Department of Internal MedicineUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Division of CardiologyUniversity of Texas Southwestern Medical CenterDallasUSA
  3. 3.Department of Clinical ScienceUniversity of Texas Southwestern Medical CenterDallasUSA
  4. 4.Division of Cardiac Surgery, St. Michael’s HospitalUniversity of TorontoTorontoCanada

Personalised recommendations